Biovica International (STO:BIOVIC-B; FRA:911) announced that it has partnered with Outcomes4Me to support post-menopausal patients with hormone (HR)-positive metastatic breast cancer (mBC) in understanding treatment protocol, prognosis, and effectiveness of their treatment regimen.
According to Biovica, its DiviTum TKa test is a blood-based biomarker test used by clinicians to assess proliferation changes in the tumor cells of their HR-positive mBC patients, providing early insights into how they are responding to CDK 4/6 inhibitors as a treatment option. The Outcomes4Me direct-to-patient empowerment platform provides personalized, evidence-based navigation to people diagnosed with cancer, and is free to patients for downloading on iOS and Android devices.
In a statement, Anders Rylander, CEO of Biovica, said, “DiviTum testing is clinically validated to be prognostic for disease progression and overall survival in mBC and we believe that all patients who are actively managing their care with CDK 4/6 inhibitors deserve to know as soon as possible whether their cancer is responding as hoped to treatment.”
“Through this new partnership with Outcomes4Me, we can raise awareness among patients with HR-positive mBC that there is a blood test readily available that can help them evaluate their treatment response far more quickly than imaging,” he added.
